Rania Abdelmaksoud

Rania Abdelmaksoud

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2017 in AMB Express
Verified
Journal Article
Open access
PDF file
ATAwatef Taktak-BenAmar
Awatef Taktak-BenAmar
MMMaram Morjen
Maram Morjen
HMHazem Ben Mabrouk
Hazem Ben Mabrouk
RARania Abdelmaksoud
Rania Abdelmaksoud
MGMohamed Guerfali
Mohamed Guerfali
AGAli Faouzi Gargouri
Ali Faouzi Gargouri
Vascular endothelial growth factor (VEGF) is associated with tumour growth and metastasis. Because VEGF is the major player in both angiogenesis and vascular permeability and the most explored factor in angio-inhibitory therapies, many expression procedures have been developed to produce functional VEGF165 in convenient yield. In this study, recombinant human VEGF165 was cloned and expressed in Escherichia coli (BL21)-DE3 cells and large scale production was performed by fermentation. A high yield of active soluble protein was obtained after protein extraction employing both lysozyme and sonication treatment. Inclusion bodies were also isolated from the cell lysate and subjected to a simple protocol of solubilisation and refolding. Single-step purification was performed using nickel affinity chromatography and the purified proteins were able to recognize monoclonal Anti-poly-His antibody. The biological activity of the VEGF165 was successfully tested using the Chicken chorioallantoic membrane assay, wound-healing migration and proliferation assay on human umbilical vein endothelial cells (HUVEC).

22 August 2022 in Genes
Verified
Journal Article
Open access
PDF file
RARania Abdelmaksoud
Rania Abdelmaksoud
NANihel Ammous
Nihel Ammous
ASAmèna Saadallah-Kallel
Amèna Saadallah-Kallel
SCSlim Charfi
Slim Charfi
SKSouhir Khemiri
Souhir Khemiri
RMRaja Mokdad-Gargouri
Raja Mokdad-Gargouri
Objectives: Several new cancer therapies targeting signaling pathways involved in the growth and progression of cancer cells were developed as personalized medicine. Our study aimed to identify epidermal growth factor receptor (EGFR) mutations for TKI treatment in non-small-cell lung cancer (NSCLC) Tunisian patients. Methods: Analysis of the TKI sensitivity mutations in exons 18 to 21 of the EGFR gene and exon 15 of the B-raf gene was performed in 79 formalin fixed-paraffin embedded (FFPE) NSCLC samples using pyrosequencing. Results: EGFR mutations were detected in 34 cases among 79 (43%), with the predominance of the L861Q in exon 21 found in 35.3% of the cases (12 out of 34). Deletions in exon 19 were found in 8 cases (23.5%), and only one young male patient had the T790M mutation. Three patients harbored composite EGFR mutations (p.E746_A750del/p.L861R, p.E746_S752>V/p.S768I, and p.G719A/p.L861Q). Furthermore, the EGFR mutated status was significantly more frequent in female patients (p = 0.019), in non-smoker patients (p = 0.008), and in patients with metastasis (p = 0.044). Moreover, the B-raf V600E was identified in 5 EGFR negative patients among 39 analyzed samples (13.15%). Conclusion: The p.L861Q localized in exon 21 of the EGFR gene was the most common mutation identified in our patients (35.3%), whereas the “classic” EGFR mutations such as Del19 and p.L858R were found in 23.5% and 11.7% of the cases, respectively. Interestingly, most of p.L861X mutation-carrying patients showed good response to TKI treatment. Altogether, our findings suggest a particular distribution of the EGFR-TKIs sensitivity mutations in Tunisian NSCLC patients.

29 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
NANihel Ammous
Nihel Ammous
RARania Abdelmaksoud
Rania Abdelmaksoud
WKWala BEN KRIDIS
Wala BEN KRIDIS
DBDorra Ben-Ayed-Guerfali
Dorra Ben-Ayed-Guerfali
SGSouhir Guidara
Souhir Guidara
RMRaja Mokdad-Gargouri
Raja Mokdad-Gargouri
Background/Objectives: This study aims to investigate the mutational spectrum of BRCA1 and BRCA2 genes in a cohort of breast cancer (BC) patients from southern Tunisia, and to evaluate their clinical and prognostic significance. Additionally, this study explores the contribution of other cancer predisposition genes and the prevalence of variants of uncertain significance (VUS). Results: Among the 165 patients included, pathogenic or likely pathogenic variants (P/LPVs) in BRCA1/BRCA2 were identified in 19 cases (11.51%), including 8 in BRCA1 and 11 in BRCA2. The presence of BRCA P/LPVs associated with young patients (p = 0.006) and those with TNBC (p = 0.036). Beyond BRCA1/2, PV/LPVs were detected in other cancer-related genes, including TP53 (n = 3), CHEK2, RAD50 (n = 2 cases each), and MUTYH, BARD1, and BRIP1 (one case each). Furthermore, 56 VUS were identified; among them, 7 were prioritized based on in silico predictive analyses, suggesting a potential deleterious effect. However, these VUS should not be used for clinical decision-making without additional evidence from functional and familial segregation studies. Conclusions: Our findings provide novel insights into the genetic landscape of breast cancer in southern Tunisia, highlighting the clinical relevance of BRCA1/2 mutations and the contribution of other susceptibility genes. These results support the personalized management of breast cancer patients and the implementation of expanded multigene panel testing in routine clinical practice to improve genetic counseling.

3 September 2026 in Cancer Reports
Verified
Journal Article
Open access
PDF file
NANihel Ammous
Nihel Ammous
RARania Abdelmaksoud
Rania Abdelmaksoud
AFAmeni Feki
Ameni Feki
SKSouhir Khemiri
Souhir Khemiri
SCSlim Charfi
Slim Charfi
RMRaja Mokdad-Gargouri
Raja Mokdad-Gargouri
Background: Ovarian cancer is one of the leading causes of death from gynecological cancer worldwide. Genetic mutations in genes involved in key cellular functions such as BRCA1/2 play a central role in tumorigenesis and have major implications for targeted therapeutic strategies, especially the use of poly (ADP‐ribose) polymerase (PARP) inhibitors. Case: Herein, we described a case of a 50‐year‐old woman diagnosed with severe anemia secondary to heavy menometrorrhagia. Initial gynecological evaluation, including transvaginal ultrasound, was unremarkable, and endometrial biopsy was not indicated. Imaging revealed no ovarian abnormalities; however, exploratory laparotomy identified a peritoneal nodule, leading to further investigation. Targeted NGS was performed on somatic and germline DNA samples and showed a frame shift deletion of 10 bp (c.1256_1265del: p.R419Ter) in the BRCA1 gene. This variant, identified only in tumor tissues, is novel and classified as pathogenic in ClinVar and ACMG databases. Additional somatic alterations were detected in TP53 and MSH6 , while germline testing revealed only a variant of uncertain significance in BARD1 . After first‐line chemotherapy, the patient benefited from olaparib and achieved a progression‐free survival of 23 months with good tolerance and no evidence of disease recurrence. Conclusion: This finding highlights the importance of integrating tumor‐based genomic profiling with germline testing to identify actionable mutations and guide precision oncology. The identification of a novel somatic BRCA1 mutation expands the mutational spectrum of HGSOC and underscores the need to include underrepresented populations, such as those from North Africa, in genomic studies.

20 January 2026 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
RARania Abdelmaksoud
Rania Abdelmaksoud
NANihel Ammous
Nihel Ammous
SCSlim Charfi
Slim Charfi
NKNesrine Kallel
Nesrine Kallel
RKRim Khemakhem
Rim Khemakhem
RMRaja Mokdad-Gargouri
Raja Mokdad-Gargouri